AVTR vs. RPRX: Avantor vs. Royalty Pharma Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.

Company profile comparison for Avantor (AVTR) and Royalty Pharma (RPRX)
Profile Item	AVTR	RPRX
Name	Avantor, Inc.	Royalty Pharma plc Class A Ordinary Shares
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	10.48 billion USD	38.70 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	June 16, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

RPRX

GSPC

Avantor (AVTR) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Royalty Pharma (RPRX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Royalty Pharma (RPRX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Total Return (1Y)	36.41%	81.08%
Total Return (3Y, Annualized)	-5.02%	39.21%
Total Return (5Y, Annualized)	-16.62%	14.22%

Risk Profile

Drawdown History

AVTR

RPRX

GSPC

Avantor (AVTR) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Royalty Pharma (RPRX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Volatility (1Y, Annualized)	43.39%	22.05%
Beta (5Y)	0.94	0.36
Max Drawdown (5Y)	-82.42%	-41.98%
Avg. Volume (3M)	8.56M	3.10M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and RPRX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Sharpe Ratio (1Y)	0.74	3.48
Sortino Ratio (1Y)	1.17	5.72

Profitability

ROE (TTM)

Royalty Pharma (RPRX) at 12.09% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for RPRX.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max: 109.18%
RPRX: 12.09%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Royalty Pharma (RPRX) at 25.70% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX: 25.70%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max: 83.12%
RPRX: 81.32%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
ROE (TTM)	5.91%	12.09%
ROA (TTM)	2.83%	5.43%
Net Margin (TTM)	5.08%	25.70%
Operating Margin (TTM)	8.19%	81.32%
Gross Margin (TTM)	31.59%	99.79%

Growth

Revenue Growth

Royalty Pharma (RPRX) at 5.06% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Royalty Pharma (RPRX) at 23.09% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Revenue Growth (YoY)	-3.41%	5.06%
Revenue Growth (3Y CAGR)	-4.46%	2.06%
EPS Growth (YoY)	-175.00%	23.09%
EPS Growth (3Y CAGR)	--	161.10%

Financial Strength

Current Ratio (MRQ)

Both Avantor (AVTR) at 1.89 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
RPRX: 1.29
Min: 0.10

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max: 1.42
RPRX: 0.88
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Current Ratio (MRQ)	1.89	1.29
Debt / Equity (MRQ)	0.63	0.88
Net Debt / EBITDA	3.40	4.76

Dividends

Dividend Yield (TTM)

Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX: 1.37%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX: 60.46%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
Dividend Yield (TTM)	0.00%	1.37%
Dividend Payout Ratio (TTM)	0.00%	60.46%

Valuation

P/E Ratio (TTM)

Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max: 85.34
RPRX: 43.99
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Royalty Pharma (RPRX) at 14.79 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max: 58.18
Q3: 25.77
RPRX: 14.79
Median: 7.30
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Avantor (AVTR) at 1.80 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max: 13.53
Q3: 6.54
RPRX: 4.39
Median: 3.25
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Royalty Pharma (RPRX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Royalty Pharma (RPRX)
Metric	AVTR	RPRX
P/E Ratio (TTM)	30.94	43.99
P/S Ratio (TTM)	1.58	14.79
P/B Ratio (MRQ)	1.80	4.39
Free Cash Flow Yield (TTM)	4.21%	-1.16%